{"id":5105,"name":"Adjuvant Capital","slug":"adjuvant-capital","website":"https://adjuvantcapital.com","hqGeo":"New York, NY","stageFocus":["Seed","Pre-Seed"],"sectorTags":["Healthcare","Other"],"excludedSectors":[],"checkSizeMin":250000,"checkSizeMax":2500000,"thesisSummary":"Invests in innovative technologies and therapies for major global health challenges, including oncology and genetic therapies.","thesisNarrative":null,"logoUrl":null,"aumUsd":300000000,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"LimmaTech Biologics","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2023,"description":"Vaccine development company working to halt AMR and STI infections.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Curevo Vaccine","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2022,"description":"Next-generation subunit vaccines, initially targeting varicella and shingles.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Memo Therapeutics","companyUrl":null,"stage":null,"sector":"Therapeutic","investmentYear":2022,"description":"Antibody discovery platform, initially targeting Nipah virus, SARS-CoV-2, CMV and BKV.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Antiva Biosciences","companyUrl":null,"stage":null,"sector":"Therapeutic","investmentYear":2021,"description":"Novel non-surgical therapeutic candidate to treat pre-cancerous cervical lesions caused by HPV.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Pulmocide","companyUrl":null,"stage":null,"sector":"Inhaled Therapeutic","investmentYear":2021,"description":"Novel therapies for patients suffering from serious acute and chronic respiratory diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Excision BioTherapeutics","companyUrl":null,"stage":null,"sector":"Therapeutic","investmentYear":2021,"description":"CRISPR-based therapies for chronic viral infectious diseases such as HIV and hepatitis B.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"LakeShore Biopharma","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2020,"description":"LakeShore is scaling up undersupplied global health vaccines and developing new biologics.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ChromaCode","companyUrl":null,"stage":null,"sector":"Platform","investmentYear":2020,"description":"ChromaCode's HD-PCR technology enhances multiplexing capabilities on existing hardware.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Codagenix","companyUrl":null,"stage":null,"sector":"Platform","investmentYear":2020,"description":"Codagenix uses emerging computational and synthetic biology tools to rationally design vaccines.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"54gene","companyUrl":null,"stage":null,"sector":"Platform","investmentYear":2020,"description":"54gene is using African genetic data to drive discoveries in drug and vaccine development.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Frontier Nutrition","companyUrl":null,"stage":null,"sector":"Lipid-Based Nutritional Supplements (LNS)","investmentYear":2020,"description":"Fortified snacks to address maternal and childhood malnutrition in Bangladesh.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"VitriVax","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2020,"description":"Thermostability and pulsatile dosing technology for vaccines and other sensitive biologics.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"MinervaX","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2020,"description":"Group B Streptococcal vaccine for the prevention of life-threatening infections in newborns.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Evofem","companyUrl":null,"stage":null,"sector":"Contraceptive","investmentYear":2020,"description":"Woman-controlled, non-hormonal contraceptive.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Univercells","companyUrl":null,"stage":null,"sector":"Process Innovation","investmentYear":2020,"description":"Univercells uses advanced manufacturing technologies to make 'Biologics for all.'","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"X-Vax","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2019,"description":"X-Vax is developing a vaccine to beat herpes.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"AN2 Therapeutics","companyUrl":null,"stage":null,"sector":"Small Molecule","investmentYear":2019,"description":"AN2 is developing novel, broad-spectrum therapeutics for infectious diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Themis","companyUrl":null,"stage":null,"sector":"Vaccine","investmentYear":2019,"description":"Themis is developing novel vaccines for high burden infectious diseases and oncology applications.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"InDevR","companyUrl":null,"stage":null,"sector":"Process Innovation","investmentYear":2019,"description":"InDevR is developing advanced characterization assays for biologics.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Tyra Biosciences","companyUrl":null,"stage":null,"sector":"Oncology","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":6,"partners":[{"id":14979,"name":"Kabeer Aziz","title":"Partner","seniority":null,"focusTags":["global health technology commercialization","emerging markets","public health innovation"],"linkedinUrl":"https://www.linkedin.com/in/kaziz107","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":14978,"name":"Glenn Rockman","title":"Managing Partner","seniority":null,"focusTags":["infectious diseases","maternal & child health","neglected tropical diseases","global health technologies"],"linkedinUrl":"https://www.linkedin.com/in/grockman","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":14980,"name":"Jenny Yip","title":"Managing Partner","seniority":null,"focusTags":["life sciences","vaccines","diagnostics","global health","sexual & reproductive health"],"linkedinUrl":"https://www.linkedin.com/in/jenny-yip","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":14981,"name":"Philippe Dro","title":"Partner","seniority":null,"focusTags":["biopharma","medical devices","vaccine development","European investments in health technologies"],"linkedinUrl":"https://www.linkedin.com/in/philippe-dro","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":14983,"name":"Gerard Cunningham","title":"Operating Partner","seniority":null,"focusTags":["operational execution","scale-up of global health technologies","manufacturing / supply chain","public health delivery"],"linkedinUrl":"https://www.linkedin.com/in/gerard-cunningham-8404415","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":14982,"name":"Kate Antrobus","title":"Venture Partner","seniority":null,"focusTags":["industrialization models","portfolio strategy","access in sub-Saharan Africa","blended finance in global health"],"linkedinUrl":"https://www.linkedin.com/in/kate-antrobus-cfa-43b886100","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[],"activity":{"lastInvestmentYear":2023,"investmentsLast12Months":0},"investorType":"vc","preferredApproach":"warm intro preferred","prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[{"id":6492,"name":"Breed Reply","slug":"breed-reply","logoUrl":null,"website":"https://www.reply.com/","stageFocus":[],"sectorTags":["Healthcare","Security"],"hqGeo":null},{"id":6827,"name":"Force Over Mass","slug":"force-over-mass","logoUrl":null,"website":"https://www.fomcap.com/","stageFocus":[],"sectorTags":["AI / ML","Developer Tools","Other","Fintech","SaaS","Healthcare","EdTech"],"hqGeo":null},{"id":1548,"name":"Health Innovation Capital","slug":"health-innovation-capital","logoUrl":null,"website":"https://www.healthinnovation.vc/","stageFocus":["Seed","Pre-Seed"],"sectorTags":["Healthcare"],"hqGeo":"Boston, MA"},{"id":12096,"name":"TeleHealth Ventures","slug":"telehealth-ventures","logoUrl":null,"website":"https://telehealthventures.com","stageFocus":["Seed"],"sectorTags":["Other","Healthcare"],"hqGeo":"Austin, TX"},{"id":1369,"name":"Sonder Health Ventures","slug":"sonder-health-ventures","logoUrl":null,"website":"https://sondercapital.com/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["Healthcare","Other"],"hqGeo":"Austin, TX, USA"},{"id":11533,"name":"Nova Health Fund","slug":"nova-health-fund","logoUrl":null,"website":"https://www.independenthealth.com/","stageFocus":["Seed","Series A"],"sectorTags":["Healthcare","Other"],"hqGeo":"Minneapolis, MN"}],"featuredIn":[{"slug":"pre-seed","displayName":"Pre-Seed Investors","pageType":"stage"},{"slug":"seed","displayName":"Seed Investors","pageType":"stage"},{"slug":"healthcare","displayName":"Healthcare Investors","pageType":"industry"}],"fundraisingResources":[{"slug":"Finding-Investors-For-Startup-In-2026","title":"How to Find Investors for Your Startup in 2026 (Without Cold-Searching Databases)"},{"slug":"how-vcs-help-portfolio-raise-follow-on","title":"How VCs Can Actually Help Their Portfolio Companies Raise Follow-On"},{"slug":"how-many-investors-should-you-pitch","title":"How Many Investors Should You Pitch? The Math Most Founders Get Wrong"}],"overviewNarrative":null,"portfolioNarrative":null,"seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-05-21T15:18:43.500Z"}